The MRDR is pleased to present their latest publication:
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction, published Jun 15 in the journal, European Journal of Haematology.
In this paper, Stephen Boyle and colleagues provide insight on the predictive ability of number of bortezomib cycles received, on survival in this cohort.
Worth a look!